TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32224326

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 35100752

Group type: EXPERIMENTAL
Intervention: Triple LET (3 applications of Lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5% every 10 minutes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single LET (1 application of Lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5% for 30 minutes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single LET
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Triple LET
Number of subjects: 48
Study: 33967755

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 590

Group type: COMPARATOR
Intervention: HCQ + LPV/r
Number of subjects: 590
Study: 35588887

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg oral twice a day for three days before CPB
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34937388

Group type: EXPERIMENTAL
Intervention: Evacetrapib (130 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 99%.
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 50%.
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both CETP inhibitors; increase in apoA1 in HDL that contains apoC1: 71% (evacetrapib) and 40% (torcetrapib).
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both CETP inhibitors; no response in HDL that contains apoL1.
Number of subjects: 206
Study: 33476880

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 811

Group type: COMPARATOR
Intervention: SC IFNB‐1a
Number of subjects: 811
Study: 32050940

Group type: EXPERIMENTAL
Intervention: GPAQ with show cards
Number of subjects: 54

Group type: COMPARATOR
Intervention: GPAQ without show cards
Number of subjects: 54
Study: 35620899

Group type: EXPERIMENTAL
Intervention: Intraoperative Portable CT Scan (PCT)
Number of subjects: 60
Study: 32514702

Group type: EXPERIMENTAL
Intervention: Medial midpatellar (MMP) injection of hyaluronic acid (HA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anteromedial (AM) injection of hyaluronic acid (HA)
Number of subjects: 100
Study: 32208774

Group type: EXPERIMENTAL
Intervention: E2 + norethisterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: E2 + progesterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: E2 + dydrogesterone
Number of subjects: 14

Group type: COMPARATOR
Intervention: E2 + placebo
Number of subjects: 14
Study: 35037049

Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 347

Group type: COMPARATOR
Intervention: PPV-23
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 35478159

Group type: EXPERIMENTAL
Intervention: Ghost Ileostomy (GI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Loop Ileostomy (LI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No Outlet (NO)
Number of subjects: 54
Study: 36201552

Group type: EXPERIMENTAL
Intervention: Robotics-assisted insertion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual insertion
Number of subjects: 12
Study: 33421446

Group type: EXPERIMENTAL
Intervention: OligoG CF-5/20 therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 32162241

Group type: EXPERIMENTAL
Intervention: WP-MND (1 or 2 servings daily, 21 g protein, 3 g leucine, 10 µg vitD, 500 mg calcium per serving)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: WP-MND (1 or 2 servings daily) during OLE
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 380
Study: 35536485

Group type: EXPERIMENTAL
Intervention: EEBS‐26 cm
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: EEBS‐30 cm
Number of subjects: 117

Group type: COMPARATOR
Intervention: CPBS
Number of subjects: 117
Study: 33599537

Group type: EXPERIMENTAL
Intervention: Axillary vein puncture guided by ultrasound (US‐Ax)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cephalic vein dissection
Number of subjects: 88
Study: 33882918

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopy
Number of subjects: 95
Study: 33746207

Group type: EXPERIMENTAL
Intervention: Dissolvable collagen punctal plugs (CPP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 64
Study: 32833890

Group type: EXPERIMENTAL
Intervention: Maintenance dose of 1.2 g·d‐1 Beta-Alanine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Interruption of supplementation
Number of subjects: 44
Study: 32973143

Group type: EXPERIMENTAL
Intervention: Mindfulness instruction (MT) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructed thinking (IT) group
Number of subjects: 0
Study: 34699772

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE300)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 29
Study: 34656202

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Couple Therapy (CBCT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Topical Lidocaine
Number of subjects: 108
Study: 33604698

Group type: EXPERIMENTAL
Intervention: Increased plasma levels of ABO protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OAS1
Number of subjects: 0
Study: 36510286

Group type: EXPERIMENTAL
Intervention: mHealth app
Number of subjects: 0
Study: 33754207

Group type: EXPERIMENTAL
Intervention: Chest X-ray (CXR) performed
Number of subjects: 597

Group type: COMPARATOR
Intervention: No CXR performed (control group)
Number of subjects: 597
Study: 34494361

Group type: EXPERIMENTAL
Intervention: New method targeting the marginal mean function for a composite endpoint including death as a component and as a competing risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard time-to-first event analyses
Number of subjects: 0
Study: 34562766

Group type: EXPERIMENTAL
Intervention: Prospective paper fall calendars
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Real-time body-worn self-reporting
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Automated body-worn detector
Number of subjects: 25
Study: 32572082

Group type: EXPERIMENTAL
Intervention: Genotype Baiana at location 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genotypes under hot semi-arid climate and tropical wet and dry climate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genotypes in restricted climatic conditions
Number of subjects: 3
Study: 35986348

Group type: EXPERIMENTAL
Intervention: Prisma intervention (psychoeducational group intervention) consisting of four weekly group sessions.
Number of subjects: 186
Study: 33973539

Group type: EXPERIMENTAL
Intervention: Systemic estrogen therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 32105162

Group type: EXPERIMENTAL
Intervention: EndoVac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RinsEndo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic activation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual needle irrigation
Number of subjects: 60
Study: 35165682

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Number of subjects: 7736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7736
Study: 34288556

Group type: EXPERIMENTAL
Intervention: Dehydrated (USG > 1.020, MDehy, FDehy, LDehy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Euhydrated (USG ≤ 1.020, MEuhy, FEuhy, LEuhy)
Number of subjects: 19
Study: 32729068

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 1484
Study: 35775843

Group type: EXPERIMENTAL
Intervention: Routine splenic flexure mobilization (SFM+), n=156
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (SFM(-)), n=67
Number of subjects: 223
Study: 33092331

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 8
Study: 35920051

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PF2.0)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Panavia V5 (PV5)
Number of subjects: 24
Study: 32111316

Group type: COMPARATOR
Intervention: 1% dietary linoleic acid (LA1%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2% dietary linoleic acid (LA2%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4% dietary linoleic acid (LA4%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 24
Study: 34281376

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Baseline glucose <150 mg/dL
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Lower baseline NIH Stroke Scale
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Internal carotid artery lesion location
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 24-hour ASPECTS
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Elevated baseline serum glucose ?150 mg/dL
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Internal carotid artery occlusion
Number of subjects: 206

Group type: COMPARATOR
Intervention: Treatment arm
Number of subjects: 206
Study: 35679195

Group type: EXPERIMENTAL
Intervention: Business case
Number of subjects: 410

Group type: COMPARATOR
Intervention: Fairness case
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study: 34446499

Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt (LPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 0
Study: 32349223

Group type: EXPERIMENTAL
Intervention: Recreational volleyball training (RV group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study: 34979996

Group type: EXPERIMENTAL
Intervention: Sufficient leisure-time physical activity (LTPA) defined as ≥600 Met minutes per week
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Motivation to be physically active during pregnancy
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Age and family income as factors affecting LTPA
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Perceived health scores
Number of subjects: 238
Study: 33809544

Group type: EXPERIMENTAL
Intervention: Polyphenol botanical blend (PBB)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 34028332

Group type: EXPERIMENTAL
Intervention: Automatic scene classification (ASC) activated
Number of subjects: 50

Group type: COMPARATOR
Intervention: No ASC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal Hearing (NH) group
Number of subjects: 50
Study: 32306953

Group type: EXPERIMENTAL
Intervention: High risk basic (HRB) group - basic prevention regimen including oral-hygiene instruction, hands-on brushing practice, supervised daytime tooth brushing, sealant application, provision of toothbrush, fluoride-containing dentifrice, and a guidebook.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High risk intensive (HRI) group - intensified preventive regimen including F-varnish application, primary molar sealant, and silver diamine fluoride (SDF) application on carious lesions.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low risk basic (LRB) group - basic prevention regimen similar to HRB group.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Comparison between HRB and HRI groups.
Number of subjects: 121
Study: 35062997

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational mindfulness based programme
Number of subjects: 0
Study: 33386796

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil infusion before balloon dilation or stent placement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil infusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (balloon dilation and stent placement only)
Number of subjects: 120
Study: 32969682

Group type: EXPERIMENTAL
Intervention: Ensemble representation - attention to statistical properties of distributions (range and mean)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenously increasing the salience of less extreme exemplars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenously increasing the salience of the distribution maximum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Largest payment made to others solving the same math problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Largest payment made to others solving different verbal problems
Number of subjects: 0
Study: 32195722

Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement containing collagen peptides (10.0 g, once-a-day)
Number of subjects: 39
Study: 36369793

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 0
Study: 33769598

Group type: EXPERIMENTAL
Intervention: Weight-based predictive equation (25 kcal/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect calorimetry (IC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permissive underfeeding (50%-80% of requirements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full feeding (100%)
Number of subjects: 0
Study: 32544794

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (Low-Int)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (Mod-Int)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Seated rest condition (REST)
Number of subjects: 24
Study: 36127117

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 84
Study: 33217874

Group type: EXPERIMENTAL
Intervention: Social Anxiety
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (suggested intervention)
Number of subjects: 74
Study: 35354530

Group type: EXPERIMENTAL
Intervention: Novel soaking solution (dexamethasone, gentamicin, and vitamin B12), soaked for 15 minutes, three times a day for four weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo liquid, soaked for 15 minutes, three times a day for four weeks.
Number of subjects: 60
Study: 33441409

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35700210

Group type: EXPERIMENTAL
Intervention: Active video game (AVG) play
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sedentary video games (SVG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-SVG sedentary behavior
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subjectively measured active play, social activities, other hobbies, television or computer/phone use
Number of subjects: 49
Study: 33430613

Group type: EXPERIMENTAL
Intervention: Chitosan‐based polymers (CBP) nasal pack
Number of subjects: 50

Group type: COMPARATOR
Intervention: Synthetic polyurethane
Number of subjects: 50
Study: 32434504

Group type: EXPERIMENTAL
Intervention: Interactive educational program including video fragments, discussion, quizzes with tailored feedback, and an exercise filling out a registration form.
Number of subjects: 0
Study: 33561824

Group type: EXPERIMENTAL
Intervention: ICE (ice vest)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (no ice vest)
Number of subjects: 12
Study: 34954100

Group type: EXPERIMENTAL
Intervention: Algorithm-based screening with ENDPAC and CT imaging
Number of subjects: 12500

Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 12500
Study: 33725907

Group type: EXPERIMENTAL
Intervention: NEFN (novel EUS-guided fine needle biopsy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CEFN (conventional EUS-guided fine needle aspiration)
Number of subjects: 56
Study: 34144965

Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 464

Group type: COMPARATOR
Intervention: Phototherapy (nb-UVB)
Number of subjects: 464
Study: 34789181

Group type: EXPERIMENTAL
Intervention: Medication+tDCS (n=15, receiving medications plus tDCS with 2 mA intensity over dorsolateral prefrontal cortex for 10 days, two sessions per day each for 20 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medication (n=15, receiving mood stabilizers including 2-5 tables of 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine two times per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medication+tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 30
Study: 35213714

Group type: EXPERIMENTAL
Intervention: GLWL‐01 (450 mg twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GLWL‐01
Number of subjects: 19
Study: 35793862

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (including exercise training, nutritional support, respiratory physiotherapy, and psychological sessions)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard pre-operative care
Number of subjects: 146
Study: 32320767

Group type: EXPERIMENTAL
Intervention: Pivotal trials for systemic therapies for plaque psoriasis
Number of subjects: 69

Group type: COMPARATOR
Intervention: Randomized controlled trials for FDA approval across various diseases
Number of subjects: 69
Study: 32806954

Group type: EXPERIMENTAL
Intervention: Glibenclamide and levcromakalim
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glibenclamide and placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 15
Study: 34910203

Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg plus MTX
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: filgotinib 100 mg plus MTX
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: filgotinib
Number of subjects: 71
Study: 33997968

Group type: EXPERIMENTAL
Intervention: Foster care with secure attachment to foster mothers
Number of subjects: 138

Group type: COMPARATOR
Intervention: Foster care with insecure attachment
Number of subjects: 138

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 138
Study: 34332159

Group type: EXPERIMENTAL
Intervention: True filtration
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham filtration
Number of subjects: 200
Study: 34244248

Group type: EXPERIMENTAL
Intervention: Integrated group‐based lifestyle programme
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Integrated group‐based lifestyle programme and standard care
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1600
Study: 32487336

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) plus Echinacea (5 ml oral suspension, 3 times daily for 10 consecutive days every month for 6 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Azithromycin (AZT) (60 mg/kg divided as 10 mg/kg/day over 6 consecutive days every month for 6 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 300
Study: 36167423

Group type: EXPERIMENTAL
Intervention: COOLING (ice slushy ingestion and application of ice towels)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HOT (no cooling)
Number of subjects: 10
Study: 33200737

Group type: COMPARATOR
Intervention: Conventional DMARDs (cyclophosphamide, mycophenolate mofetil, rituximab, tocilizumab, methotrexate)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HSCT (hypothetical based on SCOT/ASTIS results)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HSCT (actual, 4 patients)
Number of subjects: 142
Study: 36244779

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 to 0.7 µg/kg/h, DEX group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-dexmedetomidine (non-DEX group)
Number of subjects: 24
Study: 34741827

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ + activity tracker
Number of subjects: 60

Group type: COMPARATOR
Intervention: Activity tracker only (attention-control group)
Number of subjects: 60
Study: 35183923

Group type: EXPERIMENTAL
Intervention: Multimodal swelling control intervention (MSI) including inelastic adjustable compression garment (CG), manual lymph drainage (MLD) massage, and home exercise program (HEP) for three weeks after TKA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (N = 56; mean age 64.3 ± 9.3y)
Number of subjects: 16
Study: 34273208

Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 372

Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 372
Study: 33764851

Group type: EXPERIMENTAL
Intervention: 20 g soy protein (∼24–26/day genistein; ∼40–43/day total isoflavones)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 g soy protein
Number of subjects: 16
Study: 34567596

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 113

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 113
Study: 34936044

Group type: EXPERIMENTAL
Intervention: OWN THE FUTURE: Pulling Together We Will (PTWW) intervention
Number of subjects: 806

Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 806
Study: 36633795

Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1064 nm Nd: YAG laser (FxPico) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 24
Study: 33497585

Group type: EXPERIMENTAL
Intervention: Irrigation group (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-irrigation group (n=10)
Number of subjects: 20
Study: 32464321

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 19435

Group type: COMPARATOR
Intervention: No Aspirin (Control)
Number of subjects: 19435
Study: 35555254

Group type: EXPERIMENTAL
Intervention: Normobaric normoxia (FiO2 = 0.21 ± 00)
Number of subjects: 12